93 5360

Pill imprint 93 5360 has been identified as Ursodiol 250 mg.

Ursodiol is used in the treatment of gallbladder disease; biliary cirrhosis; nonalcoholic fatty liver disease and belongs to the drug class gallstone solubilizing agents. There is no proven risk in humans during pregnancy.

Ursodiol 250 mg is not subject to the Controlled Substances Act.
See also related documents.

Ursodiol Images

Ursodiol

Imprint:: 93
5360
Strength:: 250 mg
Color:: White
Size:: 14.00 mm
Shape:: Elliptical / Oval
Availability:: Prescription only
Inactive Ingredients:: cetyl alcohol
silicon dioxide colloidal
dibutyl sebacate
ethylcellulose
hypromellose
magnesium stearate
microcrystalline cellulose
polyethylene glycol
povidone
sodium lauryl sulfate
Drug Class:: Gallstone solubilizing agents
Pregnancy Category:: B - No proven risk in humans
CSA Schedule:: N - Not a controlled drug
Manufacturer:: Teva Pharmaceuticals USA
National Drug Code (NDC):: 00093-5360

View Drug Details Print Page

More Ursodiol resources

Ursodiol (Wolters Kluwer)
ursodiol (Cerner Multum)
ursodiol (Micromedex) - Includes Dosage Information
Ursodiol (AHFS DI)
Ursodiol (FDA)
Ursodiol Capsules (FDA)
Ursodiol (Wolters Kluwer)

Ursodiol is associated with the treatment of:

Search Again

Search by Imprint, Shape or Color

Note: All fields optional. Use the pill finder to identify medications by visual appearance or name.

Imprint:
Color:
Shape:

Sign In or Register

Forgot password?

Related Ursodiol Information

Availability Prescription only

CSA Schedule Not a controlled drug

Pregnancy Category No proven risk in humans

Approval History Drug history at FDA

Reviews

Average User Rating

7 User Reviews

8.4

Rate it!

Related Pages

Drug Class

Gallstone solubilizing agents

Recently Approved

Mitosol
Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.
Sklice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ...
Jentadueto
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ...
Kalydeco
Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated ...
Erivedge
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ...

More...

FDA Consumer Updates

More FDA Updates...

Related News and Articles

Fatty Liver Disease Doesn't Affect Survival, Study Finds 28 November 2011
A condition called non-alcoholic fatty liver disease (NAFLD) does not increase the risk of death, according to a new study finding that surprised Johns Hopkins...
Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 Antibodies 7 November 2011
Nonalcoholic steatohepatitis (NASH) is a major cause of cirrhosis and is growing in incidence in the United States. By treating patients with NASH with...
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis 13 October 2011
Abstract Accepted for Presentation at the European Association for Study of the Liver Special Conference on Liver Transplantation -- NEWTON,...
Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2 June 2011
Obesity and insulin resistance constitute a greater risk for fatty liver disease than moderate alcohol consumption, according to a new study that found...
Vitamin E, Diabetes Drug May Not Ease Obesity-Linked Liver Trouble in Kids 26 April 2011
Neither vitamin E nor the diabetes medication metformin worked any better than a placebo in treating fatty liver disease in children, according to new...

Get Updates by Email

Email me about ursodiol systemic:

Did you find this page helpful? Yes No

Support

About Drugs.com

Your Privacy

Follow us on: Google+ Facebook Twitter

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.

Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.

We comply with the HONcode standard for trustworthy health information.
Verify here

Terms of Use · Privacy Policy